<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00302523</url>
  </required_header>
  <id_info>
    <org_study_id>NJCT-0603</org_study_id>
    <nct_id>NCT00302523</nct_id>
  </id_info>
  <brief_title>Tacrolimus Treatment of Patients With Idiopathic Membranous Nephropathy</brief_title>
  <official_title>Tacrolimus Treatment of Patients With Idiopathic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is:&#xD;
&#xD;
        -  To explore the potential role of tacrolimus in the treatment of membranous nephropathy.&#xD;
&#xD;
        -  To investigate the safety and tolerability of tacrolimus vs methylprednisolone plus&#xD;
           cyclophosphamide.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Idiopathic membranous nephropathy is the most common cause of nephrotic syndrome in adults.&#xD;
      Over the past decade, a number of studies have reported therapeutic efficacy for treatment&#xD;
      with Cyclosporine-A (CSA) in patients with nephrotic syndrome including patients with&#xD;
      membranous nephropathy. This study will evaluate the safety and effectiveness of a new&#xD;
      calcineurin immunosuppressive drug, tacrolimus (FK506), in reducing the amount of protein in&#xD;
      the urine in patients with membranous nephropathy. Forty patients with biopsy-proven&#xD;
      membranous nephropathy will be recruited. Candidates must have completed at least six month&#xD;
      of treatment with a stable dose of angiotensin converting enzyme (ACE) inhibitors or&#xD;
      angiotensin receptor blockers (ARBs). They will be screened with a medical history, physical&#xD;
      examination, blood tests, and an examination for infection, cancers, and other conditions&#xD;
      that can cause membranous nephropathy. The investigators plan to conduct an open-label study&#xD;
      of the efficacy and safety of tacrolimus in the treatment of membranous nephropathy. They&#xD;
      will be treated with oral tacrolimus for 6 months, followed by 6 months of maintenance.&#xD;
      Proteinuria, renal function will be monitored. Complete remission is defined as 24-hour&#xD;
      urinary protein excretion to less than 0.4 mg/day. This study will explore the potential role&#xD;
      of tacrolimus in the treatment of membranous nephropathy, which is usually resistant to&#xD;
      conventional therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To explore the potential role of tacrolimus in the treatment of membranous nephropathy.</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To investigate the safety and tolerability of tacrolimus vs intravenous CTX pulse.</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Idiopathic Membranous Nephropathy</condition>
  <arm_group>
    <arm_group_label>FK506</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>FK506,0.1mg/kg/d</description>
    <arm_group_label>FK506</arm_group_label>
    <other_name>Tacrolimus,Prograf</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Biopsy-proven idiopathic membranous nephropathy&#xD;
&#xD;
          -  Nephrotic syndrome with proteinuria ( &gt; 4 g/day) and serum albumin &lt; 30 g/dl&#xD;
&#xD;
          -  Age 18-60 years with informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with abnormal liver function tests&#xD;
&#xD;
          -  Prior therapy with sirolimus, CSA, MMF, or azathioprin, cytoxan, chlorambucil,&#xD;
             levamisole, methotrexate, or nitrogen mustard in the last 90 days&#xD;
&#xD;
          -  Active/serious infection&#xD;
&#xD;
          -  Patient with hepatitis B surface antigen or who is hepatitis C antibody positive&#xD;
&#xD;
          -  Patient who is diabetic&#xD;
&#xD;
          -  Patient is allergic or intolerant to macrolide antibiotics or tacrolimus&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhi-hong Liu, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute of Nephrology, Jinling Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>March 13, 2006</study_first_submitted>
  <study_first_submitted_qc>March 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2006</study_first_posted>
  <last_update_submitted>February 2, 2012</last_update_submitted>
  <last_update_submitted_qc>February 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanjing University School of Medicine</investigator_affiliation>
    <investigator_full_name>Zhi-Hong Liu, M.D.</investigator_full_name>
    <investigator_title>Research Institute of Nephrology</investigator_title>
  </responsible_party>
  <keyword>Idiopathic Membranous Nephropathy</keyword>
  <keyword>Treatment</keyword>
  <keyword>Tacrolimus</keyword>
  <keyword>Cyclophosphamide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, Membranous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

